Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
Torres
Harrys A
HA
Barnett
Ben J
BJ
Arduino
Roberto C
RC
D002219:Carbamates / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005663:Furans; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D010755:Organophosphates / Q000008:administration & dosage*; D011336:Probability; D012189:Retrospective Studies; D012307:Risk Factors; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D006454:Hemoglobins; D010755:Organophosphates; D013449:Sulfonamides; C426859:fosamprenavir